Oculis Holding
OCS
Oculis Holding (OCS) news
Recent news
Oculis to highlight Licaminlimab at EyeCelerator @ AAO 2026 and partner with neuro-ophthalmology subspecialty day
Oculis is set to present Licaminlimab at the EyeCelerator event during the American Academy of Ophthalmology (AAO) 2026 conference, with a focus on neuro-ophthalmic innovation . The company will also collaborate with the neuro-ophthalmology subspecialty day, further emphasizing its commitment to…
AInvest Wire · Oct 7, 2026Oculis announces resignation of Lionel Carnot from board of directors
AInvest Wire · Sep 30, 2026Oculis signs asset purchase agreement with Accure Therapeutics for lead candidate, PrivosegTor, fortifying Oculis’ position as an emerging leading neuro-ophthalmology company
AInvest Wire · Aug 10, 2026Oculis Holding Oculis signs asset buy pact with Accure Therapeutics for lead candidate, PrivosegTor, fortifying Oculis'
AInvest Wire · Aug 10, 2026Oculis Holding AG - FDA confirms existing PrivoSegtor data can be used for IND application in acute MS relapses planned for submission in Q4
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.